Schizophrenia treatment based on practice guidelines;Leitlinienbasierte therapie der schizophrenie

Nervenheilkunde

Volumn 28, Issue 7, 2009, Pages 448-455

  Wobrock, T ^a   Weinmann, S ^b   Falkai, P ^a   Gaebel, W ^c  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Evidence based medicine; Guideline development; Schizophrenia; Treatment recommendation

Indexed keywords

ACAMPROSATE; AMISULPRIDE; ANTIARRHYTHMIC AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIPERIDEN; CHLORPROMAZINE; CLOZAPINE; DISULFIRAM; GLUCOSE; HALOPERIDOL; LORAZEPAM; MIRTAZAPINE; NALTREXONE; NEUROLEPTIC AGENT; NIZATIDINE; OLANZAPINE; PERAZINE; PROMETHAZINE; QUETIAPINE; RANITIDINE; REBOXETINE; RISPERIDONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID; ZIPRASIDONE; ZOTEPINE;

ACUTE PSYCHOSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; DIABETES MELLITUS; DRUG EFFICACY; EXTRAPYRAMIDAL SYNDROME; GLUCOSE BLOOD LEVEL; HUMAN; LIPID METABOLISM; LONG TERM CARE; NEGATIVE SYNDROME; PRACTICE GUIDELINE; RELAPSE; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA; SIDE EFFECT; TARDIVE DYSKINESIA; WEIGHT GAIN;

EID: 67650506921     PISSN: 07221541     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1628659     Document Type: Review

References (40)

1. Adams CE et al. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001; 179: 290-299. (Pubitemid 32996037)
2. Allison DB et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686-1696. (Pubitemid 29517559)
3. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Erarbeitung von Leitlinien für Diagnostik und Therapie. Kriterien für die Qualität von Leitlinien 2004. http://www.awmf-online.de/; oder http://leitli nien.net/
4. Baldessarini RJ, Cohen BM, Teicher MH. Significance of neuroleptic dose ans plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 1988; 45: 79-91. (Pubitemid 18018573)
5. Bollini P et al. Antipsychotic drugs: is more worse? a meta-analysis of the published randomized control trials. Psychol Med 1994; 24: 307-316. (Pubitemid 24158845)
6. Bustillo JR et al. Differential effect of clozapine on weight: a controlled study. Am J Psychiatry 1996; 153: 817-819. (Pubitemid 26170545)
7. Caspari D, Wobrock T. Cannabispsychosen - Vom eigenständigen Krankheitsbild zum Komorbiditätsmodell. Sucht 2004; 50 (5): 320-326. (Pubitemid 39486608)
8. Chakos M et al. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 2001; 158 (4): 518-526. (Pubitemid 32289814)
9. Correll CU et al. Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry 2003; 160 (11): 2063-2065. (Pubitemid 39619650)
10. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004; 161 (3): 414-425. (Pubitemid 38326094)
11. Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN) (Hrsg.). S3-Praxisleitlinien Psychiatrie und Psychotherapie. Band 1. Behandlungsleitlinie Schizophrenie. Leitlinienprojektgruppe: W. Gaebel, P. Falkai, S. Weinmann, T. Wobrock. Darmstadt: Steinkopff-Verlag 2006.
12. Dixon LB, Lehman AF, Levine J. Conventional antipsychotic medications for schizophrenia. Schizophr Bull 1995; 21(4): 567-577.
13. Falkai P et al. WFSBP Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. World J Biol Psychiatry 2005; 6(3): 132-191.
14. Gaebel W et al. First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies. Schizophr Res 2002; 53: 145-159. (Pubitemid 33139783)
15. Gaebel W et al. Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia. One-year results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry 2007; 68: 1763-1774. (Pubitemid 350247506)
16. Glassman AH, Bigger JT Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001; 158: 1774-1782. (Pubitemid 33054769)
17. Harvey PD, Keefe RSE. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 2001; 158: 176-184. (Pubitemid 32116511)
18. Jones PB et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006; 63(10): 1079-1087 (Pubitemid 44498387)
19. Kahn RS et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008; 371(9618): 1085-1097
20. Kane JM, Woerner M, Lieberman J. Tardive dyskinesia: prevalence, incidence, and risk factors. J Clin.Psychopharmacol 1988; 8: 52S-56S. (Pubitemid 18214346)
21. Kissling W. Guidelines for neuroleptic relapse prevention. Berlin: Springer Verlag 1991.
22. Kohen D. Diabetes mellitus and schizophrenia: historical perspective. Br J Psychiatry 2004; 184 (Suppl 47): s64-66. (Pubitemid 38482545)
23. Lehman AF, Steinwachs DM and PORT Co-investigators. Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull 1998; 24: 1-10. (Pubitemid 28128486)
24. Lehman AF et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004; 161: 1-56. (Pubitemid 38425473)
25. Leucht S et al. Relapse prevention in schizophrenia with new generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003; 160: 1209-1222. (Pubitemid 41070936)
26. Lieberman JA et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353(12): 1209-1223.
27. Lindenmayer JP et al. Changes in glucose and cholesterol levels in patients with schizophrenia treatedwith typical or atypical antipsychotics. Am J Psychiatry 2003; 160(2): 290-296. (Pubitemid 41110454)
28. Lindenmayer JP et al. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia. J Clin Psychiatry 2007; 68(3): 368-379 (Pubitemid 46506800)
29. McGorry et al. Summary Australian and New Zealand clinical practice guideline for the treatment of schizophrenia. Australasian Psychiatry 2003; 11(2): 136-147. (Pubitemid 36805724)
30. Möller HJ. Management of the negative symptoms of schizophrenia. New treatment options. CNS Drugs 2003; 17(11): 793-823.
31. National Institute for Clinical Excellence. Core Interventions in the Treatment of Schizophrenia. NICE, London, 2003. www.nice.org.uk
32. Schooler N et al. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry 2005; 162(5): 947-953. (Pubitemid 40676208)
33. Sepehry AA et al. Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis. J Clin Psychiatry. 2007; 68(4): 604-610 (Pubitemid 46663044)
34. Stahl SM, Grady MM. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Curr Med Chem 2004; 11(3): 313-327 (Pubitemid 38240209)
35. Tarrier N et al. Durability of the effects of cognitivebehavioural therapy in the treatment of chronic schizophrenia: 12-month follow-up. Br J Psychiatry 1999; 174: 500-504. (Pubitemid 29278683)
36. Waraich PS et al. Haloperidol dose for the acute phase of schizophrenia (Cochrane Review). In: The Cochrane Library, Issue 2. Chichester, UK: John Wiley & Sons, Ltd 2004.
37. Wobrock T, Falkai P. Leitliniengestützte Therapie schizophrener Psychosen. INFO Neurologie & Psychiatrie 2003; 5: 34-45.
38. Wobrock T et al. Schizophrenie und Sucht. Psycho- Neuro 2005; 31(9): 433-440. (Pubitemid 41494912)
39. Wobrock T, Soyka M. Pharmacotherapy of schizophrenia with comorbid substance use disorder - Reviewing the evidence and clinical recommendations. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32(6): 1375-1385.
40. Wobrock T, Falkai P. Kombinationstherapie schizophren Erkrankter jenseits der Polypharmazie. J Neurol Neurochirg Psychiatr 2008; 9: 32-38.